

# References

## Chapter 31

- 1 Bigdeli M, Jacobs B, Tomson G, Laing R, Ghaffar A, Dujardin B, Van Damme W. Access to medicines from a health systems perspective. *Health Policy and Planning*. 2013;**28**:692–704.
- 2 UN Millennium Development Goals 8E. Available from: <http://www.un.org/millenniumgoals/> (last accessed 18 November 2015).
- 3 World Health Organization. Available from: <http://www.who.int/mediacentre/news/statements/2009/access-medicines-20090313/en/> (last accessed 18 November 2015).
- 4 Frost L, Reich M. Access: How Do Good Health Technologies Get to Poor People in Poor Countries? Cambridge, MA, Harvard University Press, 2008.
- 5 World Health Organization. Available from: <http://www.who.int/mediacentre/factsheets/2003/fs275/en/> (last accessed 18 November 2015).
- 6 Malmstrom R, Godman B, Diogene E et al. Dabigatran – a case history demonstrating the need for comprehensive approaches to optimise the use of new drugs in the future. *Frontiers in Pharmacology*. 2013;**4**:1–19.
- 7 Taylor L. Australian govt blocks subsidies for new drugs. *PharmaTimes*. 15 March 2011. Available from: [http://www.pharmatimes.com/Article/11-03-15/Australian\\_govt\\_blocks\\_subsidies\\_for\\_new\\_drugs.aspx](http://www.pharmatimes.com/Article/11-03-15/Australian_govt_blocks_subsidies_for_new_drugs.aspx) (last accessed 18 November 2015).
- 8 EvaluatePharma. Surveying Tomorrow's BioPharma Landscape: The NASDAQ Biotech Index Up Close. Available from: [http://info.evaluatepharma.com/rs/evaluatepharmaltd/images/EvaluatePharma\\_NBI\\_Up\\_Close\\_2012.pdf](http://info.evaluatepharma.com/rs/evaluatepharmaltd/images/EvaluatePharma_NBI_Up_Close_2012.pdf) (last accessed 18 November 2015).
- 9 Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. *Lancet*. 2009;**373**(9659):240–9.
- 10 World Health Organization. Essential Medicines and Health Products. Available from: [http://www.who.int/medicines/services/essmedicines\\_def/en/](http://www.who.int/medicines/services/essmedicines_def/en/) (last accessed 18 November 2015).
- 11 Organisation for Economic Co-operation and Development. Health at a Glance 2013: OECD Indicators. Available from: <http://www.oecd.org/els/health-systems/Health-at-a-Glance-2013.pdf> (last accessed 18 November 2015).
- 12 Mao W, Tang S, Chen W. Does perverse economic incentive lead to the irrational use of medicines? *Expert Review of Pharmacoeconomics & Outcomes Research*. 2013;**13**(6):693–6.
- 13 Putrik P, Ramiro S, Kvien TK, Sokka T, Pavlova M, Uhlig T, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. *Annals of Rheumatic Disease*. 2014;**73**:198–206.
- 14 Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing. *Journal of the American Medical Association*. 2007;**298**(1):61–9.
- 15 Gustafsson LL, Wettermark B, Godman B, Andersén-Karlsson E, Bergman U, et al. The 'Wise List' – a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. *Basic & Clinical Pharmacology & Toxicology*. 2011;**108**:224–33.
- 16 Jappy B, Krska J, Downie GA, Smith ME, Williams A, Petrie JC. The Grampian Hospitals Drug Formulary. *Health Bulletin*. 1989;**47**:223–6.
- 17 Garvey G, Jappy B, Stewart D, Williams A, Duffus PR, Maitland JM, et al. Grampian Health Board's joint drug formulary. *British Medical Journal*. 1990;**301**:851–2.
- 18 Stewart DC, Milne K, Krska J, Downie G. Adherence to the Grampian joint drug formulary in general practice. *Journal of Clinical Pharmacy and Therapeutics*. 1996;**21**:79–82.

- 19 Godman B, Campbell S, Suh HS, Finlayson A, Bennie M, Gustafsson L. Ongoing measures to enhance prescribing efficiency across Europe: implications for other countries. *Journal of Health Technology Assessment*. 2013;**1**:27–42.
- 20 Godman B, Wettermark B, van Woerkom M, Fraeyman J, Alvarez-Madrado S, Berg C, et al. Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications. *Frontiers in Pharmacology*. 2014;**5**:106.
- 21 Dylst P, Vulto A, Godman B, Simoens S. Generic medicines: solutions for a sustainable drug market? *Applied Health Economics and Health Policy*. 2013;**11**(5):437–43.
- 22 World Health Organization. *Drug and Therapeutic Committees, A Practical Approach*. Geneva, World Health Organization, 2003.
- 23 Bjorkhem-Bergman L, Andersen-Karlsson E, Laing R, Diogene E, Melien O, Jirlow M, et al. Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations. *European Journal of Clinical Pharmacology*. 2013;**69**(Suppl. 1):73–8.
- 24 Torgesen I. Access to some NICE approved drugs varies hugely across England. *British Medical Journal*. 2014;**348**:g465.
- 25 World Bank. 2013 World Development Indicators. Available from: <http://databank.worldbank.org/data/download/WDI-2013-ebook.pdf> (last accessed 18 November 2015).
- 26 Filion KB, Delaney CJ A, Brophy JM, Ernst P, Suissa S. The impact of over-the-counter simvastatin on the number of statin prescriptions in the United Kingdom: a view from the General Practice Research Database. *Pharmacoepidemiology & Drug Safety*. 2007;**16**:1–4.
- 27 World Health Organization. Essential Medicines and Health Products Information Portal: A World Health Organization Resource. WHO Drug Information Vol. 15, No. 3 & 4, 2001. Last accessed: <http://apps.who.int/medicinedocs/en/d/Jh2989e/> (18 November 2015).
- 28 Laing BA, Mackey TK. Prevalence and global health implications of social media in direct-to-consumer drug advertising. *Journal of Medical Internet Research*. 2011;**13**(3):e64.
- 29 McNaughton R, Huet G, Shakir S. An investigation into drug products withdrawn from the EU market between 2002 and 2011 for safety reasons and the evidence used to support the decision-making. *British Medical Journal Open*. 2014;**4**(1):e004221.
- 30 Merck. Merck Announces Voluntary Worldwide Withdrawal of VIOXX®. 30 September 2004. Available from: <http://www.pbm.va.gov/vacenter-formedicationsafety/vioxx/DearHealthcareProfessional.pdf> (last accessed 18 November 2015).
- 31 Davies N, Jamali F. Cox-2 selective inhibitors cardiac toxicity: getting to the heart of the matter. *Journal of Pharmacy & Pharmaceutical Science*. 2004;**7**:332–6.
- 32 Bresalier R, Sandler R, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. *New England Journal of Medicine*. 2005;**352**(11):1092–102.
- 33 Weir MR, Sperling RS, Reicin A, Gertz BJ. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. *American Heart Journal*. 2003;**146**:591–604.
- 34 Bombardier L, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. *New England Journal of Medicine*. 2000;**343**:1520–8.
- 35 Food and Drug Administration. Vioxx (Rofecoxib) May 2002. Available from: <http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlerts-forHumanMedicalProducts/ucm154520.htm> (last accessed 18 November 2015).
- 36 Calfee JE, Pinell X. Prepared for a conference on consumers, information, and the evolving health-care market place. Available from: <http://www.aei.org/papers/health/the-significance-of-the-vioxx-withdrawal/> (last accessed 18 November 2015).
- 37 Quick JD, Hogerzeil HV, Velasquez G, Rago L. Twenty-five years of essential medicines. *Bulletin of the World Health Organization*. 2002;**80**(11):913–14.
- 38 World Health Organization. Surge in demand leads to shortage of artemisinin-based combination therapy for malaria. Available from: <http://www.who.int/mediacentre/news/releases/2004/pr77/en/> (last accessed 18 November 2015).
- 39 Neuman J, Korenstein D, Ross JS, Keyhani S. Prevalence of financial conflicts of interest among panel members producing clinical practice guidelines in Canada and United States: cross sectional study. *British Medical Journal*. 2011;**343**:d5621.

- 
- 40** AGREE Research Trust. Appraisal of Guidelines for Research and Evaluation II. Available from: [http://www.agreetrust.org/wp-content/uploads/2013/10/AGREE-II-Users-Manual-and-23-item-Instrument\\_2009\\_UPDATE\\_2013.pdf](http://www.agreetrust.org/wp-content/uploads/2013/10/AGREE-II-Users-Manual-and-23-item-Instrument_2009_UPDATE_2013.pdf) (last accessed 18 November 2015).
- 41** Cohen-Kohler JC. The morally uncomfortable drug gap. *Clinical Pharmacology and Therapeutics*. 2007;**82**(5):610–14.
- 42** Busfield J. ‘A pill for every ill’: explaining the expansion in medicine use. *Social Science Medicine*. 2010;**70**:934–41.
- 43** Vernaz N, Haller G, Girardin F, Huttner B, Combescure C, Dayer P, et al. Patented drug extension strategies on healthcare spending: a cost-evaluation analysis. *PLoS Medicine*. 2013;**10**(6):e1001460.
- 44** Light DW, Lexchin J, Darrow JJ. Institutional corruption of pharmaceuticals and the myth of safe and effective drugs. *Journal of Law, Medicine & Ethics*. 2013;**41**(3):590–600.